Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. All podium presentation sessions will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time (U.S. ET) specified in the program. Poster presentations will not be available for viewing on-demand.

Program in progress.

*-Short talk from proffered abstract

Thursday, October 23

• Plenary Session 1: Targeting RAS
• Plenary Session 2: Radiopharmaceuticals
• Spotlight on Proffered Papers 1
• Keynote Lecture
• Concurrent Session 1-3
  • AACR Project GENIE: Powering Drug Discovery Through an International Consortium
  • Bispecifics/T-cell Engagers
  • Protein Degraders
• AACR Chemistry in Cancer Research Working Group (CICR) Town Hall

Continental Breakfast

7-8 a.m. | Level 3, Ballroom Foyer and Bolyston Street Hallway

Plenary Session 1: Targeting RAS

8-9:40 a.m. | Level 3, Ballroom AB

Session Cochairs: David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas

• 8:05 a.m.
  Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
• 8:30 a.m. | Targeting the oncogenic state of RAS with tri-complex inhibitors
  Jan Smith, Revolution Medicines, Redwood City, California
• 8:55 a.m. | Targeting RAS: What have we learned? What are we learning? What do we need to learn?
  David S. Hong
• 9:20 a.m. | Panel Discussion

Break

9:40-10 a.m.

Plenary Session 2: Radiopharmaceuticals

10-11:40 a.m. | Level 3, Ballroom AB

Session Cochairs: Alessandra Gennari, University of Piemonte Orientale, Novara, Italy, and Oliver Sartor, Tulane University School of Medicine, New Orleans, Louisiana

• 10:05 a.m. | Critical factors in design of ligands useful for molecularly targeted radiation
  John Babich, Ratio Therapeutics, Boston, Massachusetts
• 10:30 a.m. | Factors important in selection of targets for radiopharmaceuticals
  H. David Ulmert, University of California, Los Angeles, California
• 10:55 a.m. | Bench to bedside in academia: Lessons learned and planning the next generation radiopharmaceuticals
  Andrei Iagaru, Stanford University, Stanford, California
• 11:20 a.m. | Panel Discussion

Spotlight on Proffered Papers 1

11:45 a.m.-12:15 p.m. | Level 3, Ballroom AB

Session Chair: Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain

• 11:45 a.m. | Resistance mechanisms to monotherapy RAS(ON) multi-selective inhibitor Daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies*
  Ida Aronchik, Revolution Medicines, Redwood City, California
• 11:55 a.m. | Directed clonal evolution: Leveraging divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation*
  Eunice Cho, The Broad Institute, Cambridge, Massachusetts
• 12:05 p.m. | Leveraging conformation selectivity of MAPK-targeting inhibitors for tumor-selective targeting of RAS-mutant cancers*
  Poulikos Poulikakos, Icahn School of Medicine at Mount Sinai, New York, New York

Exhibit Show

12-4 p.m. | Level 2, Exhibit Hall D

Poster Session A

12:30-4 p.m. | Level 2, Exhibit Hall D

Keynote Lecture

4:15-5 p.m. | Level 3, Ballroom AB

• 4:15 p.m. | Introduction
• Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
• 4:20 p.m. | Keynote Speaker
  A tale of two biomarkers: Improving outcomes for cancer of unknown primary and recurrent early stage non-small cell lung cancer
  Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom
• 4:50 p.m. | Discussion / Q&A

Concurrent Sessions 1-3

5-6:40 p.m.

Concurrent Session 1: AACR Project GENIE: Powering Drug Discovery Through an International Consortium

Level 3, Rooms 302/304

Session Chair: Kenneth L. Kehl, Dana-Farber Cancer Institute, Boston, Massachusetts

• 5 p.m. | Using GENIE data for clinico-genomic research
  Kenneth L. Kehl
• 5:30 p.m. | Off-label targeted therapy utilization in the GENIE BPC datasets
  Jeremy L. Warner, Legorreta Cancer Center at Brown University, Providence, Rhode Island
• 5:55 p.m. | Using GENIE data to drive oncology target identification and drug development
  Phillip Beer, Step Pharma, Cambridge, United Kingdom
• 6:20 p.m. | Panel Discussion / Q&A

Concurrent Session 2: Bispecifics/T-cell Engagers

Level 3, Ballroom AB

Session Cochairs: Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain and Lillian L. Siu, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

• 5:05 p.m. | An affinity and architecture roadmap to impact for precision T cell engagers
  Alan J. Russell, Amgen, Thousands Oaks, California
• 5:30 p.m. | Clinical development of T-cell engagers
  Ben Tran, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
• 5:55 p.m. | Bispecifics beyond cell engagers
  Elena Garralda
• 6:20 p.m. | Updated safety, efficacy, and biomarker analysis from the Phase I Study of Givastomig, a novel Claudin 18.2/4-1BB bispecific antibody, in Claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)*
  Samuel Klempner, Massachusetts General Hospital, Boston, Massachusetts

Concurrent Session 3: Protein Degraders

Level 3, Ballroom C

Session Cochairs: Katrina L. Jackson, C4 Therapeutics, Watertown, Massachusetts, and Victor Moreno, START Madrid, Madrid, Spain

• 5:05 p.m. | PROTACS in oncology, targeted therapy of the future?
  Victor Moreno
• 5:30 p.m. | Unveiling the hidden intercom of CRBN molecular glues
  Katherine Donovan, Dana-Farber Cancer Institute, Boston, Massachusetts
• 5:55 p.m. | Discovery and characterization of a clinical-stage molecular glue degrader of WEE1 kinase, BMS-986463, for the treatment of advanced solid tumors
  Joshua Baughman, Bristol Myers Squibb, San Diego, California
• 6:20 p.m. | PXG-CycK, a highly selective molecular glue degrader of Cyclin K with potent anti-tumor activity in HER2-amplified cancers*
  Matthias Brand, Proxygen, Vienna, Austria

AACR Chemistry in Cancer Research Working Group (CICR) Town Hall: The Promise of Molecular Glues in Cancer Treatment – Will it Stick?

6:45-8:15 p.m. | Level 3, Rooms 302/304

Moderator: Daniel La, TRIANA Biomedicines, Brookline, Massachusetts

• 6:45 p.m. | Reception
• 7:15 p.m. | Town Hall
  Panelists:
  Katherine Donovan, Dana-Farber Cancer Institute, Boston, Massachusetts
  Jannik N. Anderson, Tango Therapeutics, Boston, Massachusetts
  Christopher Nasveschuk, C4 Therapeutics, Watertown, Massachusetts